Literature DB >> 21901167

Cooperative Cross-Talk between Neuroblastoma Subtypes Confers Resistance to Anaplastic Lymphoma Kinase Inhibition.

Xiaocai Yan1, Colin R Kennedy, Sarah B Tilkens, Olena Wiedemeier, Hong Guan, Jong-In Park, Andrew M Chan.   

Abstract

Neuroblastoma is a pediatric solid tumor that can be stratified into stroma-rich and stroma-poor histological subgroups. The stromal compartment of neuroblastoma is composed mostly of Schwann cells, and they play critical roles in the differentiation, survival, and angiogenic responses of tumor cells. In certain neuroblastoma cell lines, the coexistence of neuroblastic N-type and substrate-adherent S-type is frequently observed. One such cell line, SK-N-SH, harbors a F1174L oncogenic mutation in the anaplastic lymphoma kinase (ALK) gene. Treatment of SK-N-SH with an ALK chemical inhibitor, TAE684, resulted in the outgrowth of S-type cells that expressed the Schwann cell marker, S100α6. Nucleotide sequencing analysis of these TAE684-resistant (TR) sublines revealed the presence of the ALK F1174L mutation, suggesting their tumor origin, although ALK protein was not detected. Consistent with these findings, TR cells displayed approximately 9-fold higher IC(50) values than N-type cells. Also, unlike N-type cells, TR cells have readily detectable phosphorylated STAT3 but weaker phosphorylated AKT. Under coculture conditions, TR cells conferred survival to N-type cells against the apoptotic effect of TAE684. Cocultivation also greatly enhanced the overall phosphorylation of STAT3 and its transcriptional activity in N-type cells. Finally, conditioned medium from TR clones enhanced cell viability of N-type cells, and this effect was phosphatidylinositol 3-kinase dependent. Taken together, these results demonstrate the ability of tumor-derived S-type cells in protecting N-type cells against the apoptotic effect of an ALK kinase inhibitor through upregulating prosurvival signaling.

Entities:  

Keywords:  ALK; Schwann cells; TAE684; neuroblastoma; stromal

Year:  2011        PMID: 21901167      PMCID: PMC3161418          DOI: 10.1177/1947601911416003

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  43 in total

1.  Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell.

Authors:  J Mora; N K Cheung; G Juan; P Illei; I Cheung; M Akram; S Chi; M Ladanyi; C Cordon-Cardo; W L Gerald
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

2.  Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis.

Authors:  A Rebbaa; P M Chou; B L Mirkin
Journal:  Mol Med       Date:  2001-06       Impact factor: 6.354

3.  Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.

Authors:  B A Spengler; D L Lazarova; R A Ross; J L Biedler
Journal:  Oncol Res       Date:  1997       Impact factor: 5.574

4.  Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.

Authors:  V Ciccarone; B A Spengler; M B Meyers; J L Biedler; R A Ross
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

5.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.

Authors:  Alberto Zamo; Roberto Chiarle; Roberto Piva; Jennifer Howes; Yan Fan; Marco Chilosi; David E Levy; Giorgio Inghirami
Journal:  Oncogene       Date:  2002-02-07       Impact factor: 9.867

6.  Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells.

Authors:  Sandra Acosta; Cinzia Lavarino; Raquel Paris; Idoia Garcia; Carmen de Torres; Eva Rodríguez; Helena Beleta; Jaume Mora
Journal:  BMC Dev Biol       Date:  2009-02-12       Impact factor: 1.978

7.  Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.

Authors:  Monica Hecht; Maria Papoutsi; Hoa Dinh Tran; Joerg Wilting; Lothar Schweigerer
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

8.  Schwann cell-conditioned medium promotes neuroblastoma survival and differentiation.

Authors:  J L Kwiatkowski; J L Rutkowski; D J Yamashiro; G I Tennekoon; G M Brodeur
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

9.  Oncogenic mutations of ALK kinase in neuroblastoma.

Authors:  Yuyan Chen; Junko Takita; Young Lim Choi; Motohiro Kato; Miki Ohira; Masashi Sanada; Lili Wang; Manabu Soda; Akira Kikuchi; Takashi Igarashi; Akira Nakagawara; Yasuhide Hayashi; Hiroyuki Mano; Seishi Ogawa
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

10.  Human neuroblastoma I-type cells are malignant neural crest stem cells.

Authors:  R A Ross; B A Spengler; C Domènech; M Porubcin; W J Rettig; J L Biedler
Journal:  Cell Growth Differ       Date:  1995-04
View more
  7 in total

1.  ALK positively regulates MYCN activity through repression of HBP1 expression.

Authors:  Shana Claeys; Geertrui Denecker; Kaat Durinck; Bieke Decaesteker; Liselot M Mus; Siebe Loontiens; Suzanne Vanhauwaert; Kristina Althoff; Caroline Wigerup; Daniel Bexell; Emmy Dolman; Kai-Oliver Henrich; Lea Wehrmann; Ellen M Westerhout; Jean-Baptiste Demoulin; Candy Kumps; Tom Van Maerken; Genevieve Laureys; Christophe Van Neste; Bram De Wilde; Olivier De Wever; Frank Westermann; Rogier Versteeg; Jan J Molenaar; Sven Påhlman; Johannes H Schulte; Katleen De Preter; Frank Speleman
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

Review 2.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

3.  Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

Authors:  Shana Claeys; Geertrui Denecker; Robrecht Cannoodt; Candy Kumps; Kaat Durinck; Frank Speleman; Katleen De Preter
Journal:  Oncotarget       Date:  2017-11-06

4.  Super-enhancer associated core regulatory circuits mediate susceptibility to retinoic acid in neuroblastoma cells.

Authors:  Roshna Lawrence Gomez; Laura M Woods; Revathy Ramachandran; Ahmad N Abou Tayoun; Anna Philpott; Fahad R Ali
Journal:  Front Cell Dev Biol       Date:  2022-09-06

Review 5.  A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.

Authors:  Mike-Andrew Westhoff; Georg Karpel-Massler; Oliver Brühl; Stefanie Enzenmüller; Katia La Ferla-Brühl; Markus D Siegelin; Lisa Nonnenmacher; Klaus-Michael Debatin
Journal:  Mol Cell Ther       Date:  2014-10-27

Review 6.  [Mechanisms of resistance to EML4-ALK inhibitors in non-small cell lung cancer].

Authors:  Di Wu; Hong Yu; Jiamei Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-01

7.  Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors.

Authors:  Jing Li; Yubing Wang; Lisha Li; Penelope M-Y Or; Chi Wai Wong; Tian Liu; Wayne L H Ho; Andrew M Chan
Journal:  Mol Oncol       Date:  2021-05-06       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.